Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide

Background and objective: Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes. It may control other metabolic processes as well. We aimed to evaluate whether exenatide helps to achieve metabolic control goals in patients with obesity and type 2 diabetes (12DM) after 24 weeks of treatment. Patients and method: Open clinical trial in 102 obese patients, with age between 19-77 years (mean [ED] 53,2 [1,1] years), T2DM with mean evolution of 4,88 [0,5] years (range 1 to 20 years) with oral antidiabetic treatment. Results: There was a reduction of 19.7 +/- 7.1 mg/dl in the fasting glucose average and of 0.33 +/- 0.17% in glycated hemoglobin (HbA(1c)). These last values were higher (2.12 +/- 0.53%) in patients with bad control prior to treatment (HbA(1c) > 8.5%). The desirable threshold of HbA(1c) <7% was fulfilled by 14% more treated than control patients (43.6 vs. 57.9, P <.05). Reductions of 4.4 +/- 0.8 kg average weight and of 1.7 +/- 0.3 kg/m(2) body mass index were recorded. Although there was not a significant reduction in the overall lipid profile, a decrease of 4.9 +/- 5.1 mg/dl total cholesterol, 3.2 +/- 4.3 mg/dl LDL-C, 8.6 +/- 5.6 mg/dl noHDL-C and 2.5 +/- 1, 4 mg/dl HDL-C was observed. Patients outside target (LDL > 100 and/or triglycerides > 150 mg/dl) showed significant differences in their concentrations of LDL-C and triglycerides. With respect to blood pressure (BP), significant differences were observed in diastolic BP (-18.9 +/- 5.7 mmHg) but not in systolic BP (P<.05). Conclusions: Exenatide is an effective drug not only for glycemic control but also for the overall metabolic control of HbA(1c), lipid profile, BP and body weight. (C) 2011 Elsevier Espana, S.L. All rights reserved.